DHSC: OHID: Cost-effectiveness model of prostate cancer screening 2nd phase

The second phase of work on the prostate cancer cost-effectiveness model will build on the initial efforts update a suitable prostate cancer cost effectiveness model, focusing on further evaluation and development of the model to influence screening programmes. To evaluate the cost-effectiveness of PSA-based screening for all men aged 45-70- and 45-75-year-old, with the frequency of testing stratified by individual risk calculated from an initial PSA, age, ethnicity, and family history (e.g., initially yearly for h...